Slide 1: Cover letter to stock exchanges: Investors/Analysts Presentation
Laurus Labs Limited Corporate Office 2"' Floor, Serene Chambers, Rood No. 7 Bonjaro Hills, Hyderobad · S0003L., Telongono, Indio T +91 L.O 3980L.333/23L.2 0500/501 LAURUSLabs F +91 40 3980 4320 Knowledge . Innovation . Excellence May 10,2018 To To The Corporate Relations Department The Listing Depar
Slide 2: Q4 & FY18 Results Presentation
LAURUS LABS LIMITED Q4 & FY18 RESULTS PRESENTATION May 10, 2018
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ mate
Slide 4: Business Snapshot
Business Snapshot Overview • Development, manufacture • Developing and manufacturing • Contract development and • Sale and manufacture of and sale of active oral solid formulations manufacturing services for specialty ingredients for use in pharmaceutical ingredients global pharmaceutical nutraceuti
Slide 5: Strategy in Motion
Strategy in Motion ARV & HEP-C Oncology & Other APIs FDFs Synthesis Ingredients • Significant increase in HIV • Leadership in select • Leverage API capabilities; • Focus on supply of key • Leverage process patient population with Oncology API. Launching capture operating starting materials and chemi
Slide 6: Transformation of Business Model
Transformation of Business Model • Crossed INR 20 billion of revenue • Commenced commercial operations from Unit 4 • Incorporated a subsidiary in Germany • Investment of • Incorporated First • Unit 2-Formulations, inspected by INR 600 Mn by Subsidiary in USA, • Successfully listed on BSE & USFDA wit
Slide 7: Significant Investments in Generic FDF Business
Significant Investments in Generic FDF Business Filed first ANDA and WHO dossier in 2016. Leverage API production and R&D capabilities to forward integrate into As on date filed nine ANDAs and one FDF NDA and in addition completed 6 validations for formulations. Filings Strategy Capture sign
Slide 8: Strong R&D Capabilities
Strong R&D Capabilities “Research-first” approach – Set up dedicated R&D Key Accreditations center in Hyderabad in 2006 prior to commissioning API manufacturing facility in 2007 R&D team comprising 750 plus scientists (25.0% of total employee strength) including over 45 PhDs Kilo Lab at R&D ce
Slide 9: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits Laurus’ Philosophy “One Quality Standard for all markets” Regular Inspection at different manufacturing units 2018 USFDA We maintain consistent quality, efficiency and product safety. 2017 WHO, USFDA, EU (Germany) 2016 USFDA We have adopted uniform manufacturing sta
Slide 10: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Vishakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 315 reactors with 1,141 Kilo Liters capacit
Slide 11: Manufacturing Facilities at Achutapuram, Vizag
Manufacturing Facilities at Achutapuram, Vizag Unit-II • Located at APIIC, Achutapuram, Visakhapatnam, India. (SEZ) • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets per year. • API block with 12 reactors with 83 Kilo Liters capacity. • Received ap
Slide 12: Business Highlights – FY 18
Business Highlights – FY 18 Overall Synthesis & Ingredients Revenue crossed INR 20 Bn mark and grew by 8 % in Commenced commercial operations from Unit 4 for FY18. global partner, C2 Pharma. R & D spent of INR 1,196 Mn and 5.9 % as percentage Commenced commercial supplies from Unit 5 to of s
Slide 13: Performance Highlights - Abridged Profit & Loss statement
Performance Highlights - Abridged Profit & Loss statement Growth % Growth % Growth % (Q4 FY18 (Q4 FY18 Particulars (Rs. mn) Q4 FY17 Q3 FY18 Q4 FY18 FY17 FY18 (FY18 Vs. Vs. Vs. FY 17) Q4 FY 17) Q3 FY 18) Total Revenues from Operations (Net) 4,728 4,789 5,602 18.5% 17.0% 19,046 20,562 8.0% Total Expen
Slide 14: Drivers of Earnings – FY 18
Drivers of Earnings – FY 18 2,000 10.0% 10.5% 23.1% 21.5% 2,500 12.3% 1,90013.5% 10.0% 4,500 24.3% 11.5% 23.3% 9.5% 4,400 22.3% 1,80012.5% 9.0% 2,300 8.2% 4,300 21.3% 1,700 8.5% 4,200 20.3% 2,100 11.5% 8.0% 19.3% 1,600 7.5% 4,100 18.3% 1,50010.5% 7.0% 1,900 17.3% 4,000 1,4009.5% 6.5% 16.3% 6.0% 3,90
Slide 15: Drivers of Revenue
Drivers of Revenue ARV Segment registered a growth of over 25% in Q4 Revenue Contribution FY18 (Y-o-Y) and by 9% in FY 18, with improved volumes 2% 4% 3% 5% 4% 8% 6% 7% 6% 8% Synthesis Business continues to report robust 9% 8% 8% 8% 12% revenue growth showing 63% increase in the 6% 9% 7% 8% quar
Slide 16: Abridged Balance Sheet
Abridged Balance Sheet As on As on Particulars (INR Mn) 31.03.2017 31.03.2018 EQUITY AND LIABILITIES Share capital 1,058 1,060 Reserves and surplus 12,247 13,766 Non-current liabilities 2,022 2,272 Current liabilities 11,207 13,069 Total 26,534 30,167 ASSETS Non-current assets 1,404 1,252 Fixed asse
Slide 17: Established Track Record Of Delivering Growth – Efficient Use of Capital and Prudent Leverage
Established Track Record Of Delivering Growth – Efficient Use of Capital and Prudent Leverage Pre Tax Return on Capital Return on Equity(2) (%) Total Debt/Equity Ratio (x) Employed(1) (%) 16.5% 16.5% 17.0% 17.4% 1.2x 1.1x 14.5% 13.6% 12.7% 11.9% 0.7x 0.6x FY15 FY16 FY17 FY 18 FY15 FY16 FY17 FY 18 FY
Slide 18: Management Team
Management Team Tom Versosky Chandrakanth Chereddi President FDF North America ED & Head, Generics FDF & Strategy Dr. Prafulla Kumar Nandi SVP, Global Regulatory Affairs Ravikumar V V G Venkateshwar Reddy (Formulations) ED &CFO CS and Sr. GM – Legal & Secretarial Dr. GSR Anjaneyulu Exec. VP & Head,
Slide 19: Corporate Governance
Corporate Governance Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Chandrakanth Chereddi Whole-time Director and Head of Generic FDF and Strategy Dr Lakshmana Rao C V Whole-time D
Slide 20: Ownership Structure
Ownership Structure Corporate Structure Laurus Labs Limited Laurus Synthesis Laurus Holdings All are 100% Sriam Labs Pvt Ltd. Inc. Ltd. Subsidiaries India USA UK Laurus Generics Laurus Generics Inc. GmbH. USA Germany Shareholding pattern * 30.6% 7.8% 10.2% 1.3% 0.03% 19.8% 11.6% 18.8% Promoter Finan
Slide 21: Laurus Labs is a Fortune 500 Company & Great Place To Work in 2018
Laurus Labs is a Fortune 500 Company & Great Place To Work in 2018 Laurus Labs is listed in the Fortune 500 Companies List Laurus Labs is certified as “Great Place to Work” for in India the year 2018. 20
Slide 22: Laurus Labs Manufacturing Units Bags Good Green Governance Award
Laurus Labs Manufacturing Units Bags Good Green Governance Award Laurus Labs bags the prestigious Srishti G3 Award for Good Green Governance in the Manufacturing Process – Non Metallurgical category. Mr. Suryadevara Srinivasa Rao, Vice President, Manufacturing, received the award from former Governo
Slide 23: Results Conference Call
Results Conference Call Results conference call on Friday May 11, 2018 at 10:30 AM IST Details of the conference call are as follows: Timing 10:30 AM IST on Friday, May 11, 2018 Conference dial-in Primary number +91 22 6280 1214 India Local access Number +91 22 7115 8115 Available all over India Sin
Slide 24: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also
Slide 25: Thank You
Thank You